header
Image from OpenLibrary

The prevalence of disease- related complications in Egyptian children and young adults with sickle cell disease receiving hydroxycarbamide / Ramy Loka Nageh ; Supervised Amina Abdelsalam Mahmoud , Mai Mohamed Mohamed Abdelsalam , Mona Ahmed Kamel

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Ramy Loka Nageh , 2020Description: 145 P. : charts , facimiles ; 25cmOther title:
  • تأثير استخدام دواء الهيدروكسى كارباميد على مضاعفات مرض الأنيميا المنجليه فى الاطفال وصغار الشباب المصريين [Added title page title]
Subject(s): Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Pediatrics Summary: Background: Although hydroxyurea has an established role in improving laboratory parameters and reducing acute clinical complications, its role in preventing organ damage in SCD is less well defined. Objectives: To assess the prevalence of disease- related complications in Egyptian patients with SCD receiving HU. Materials and Methods: This is a retrospective analytic study carried out on 60 SCD patients who were receiving HU therapy for at least 1 year. Details of HU therapy, clinical and laboratry data before and after HU were recorded. Results: All patients received HU at a starting dose 15 mg/kg/day with a maximum tolerated dose reached 35 mg/kg/day in 2 patients. Mean HU dose was 19 ± 4.9 mg/ kg/day and mean duration of HU treatment was 6.2 years.There was significant reduction in the frequency of vasoocclusive crises per year, frequency of blood transfusion and rate of hospitalization (p{u02C2}0.05). No significant difference was detected before and after using HU as regards the frequency infections, sequestration, aplastic crises, leg ulcers and cardiac complications (p{u02C3}0.05). One patient developed leg ulcers and another one had pulmonary hypertension while on HU. None of the studied patients had evidence of avascular necrosis at starting HU, however, eight (13.3%) patients developed bone changes while on HU. Two (3.4%) patients developed stroke while on HU and they were shifted to chronic transfusion regimen. There were a significant increases in total Hb, and significant decrease in TLC and reticulocytic count (p{u02C2}0.05). A statistically significant improvement of school scores among patients was seen after HU treatment (P=0.025). A marginally significant improvement of quality of life scores was detected among patients after using HU (P=0.05)
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Date due Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.11.28.M.Sc.2020.Ra.P (Browse shelf(Opens below)) Not for loan 01010110082058000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.11.28.M.Sc.2020.Ra.P (Browse shelf(Opens below)) 82058.CD Not for loan 01020110082058000

Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Pediatrics

Background: Although hydroxyurea has an established role in improving laboratory parameters and reducing acute clinical complications, its role in preventing organ damage in SCD is less well defined. Objectives: To assess the prevalence of disease- related complications in Egyptian patients with SCD receiving HU. Materials and Methods: This is a retrospective analytic study carried out on 60 SCD patients who were receiving HU therapy for at least 1 year. Details of HU therapy, clinical and laboratry data before and after HU were recorded. Results: All patients received HU at a starting dose 15 mg/kg/day with a maximum tolerated dose reached 35 mg/kg/day in 2 patients. Mean HU dose was 19 ± 4.9 mg/ kg/day and mean duration of HU treatment was 6.2 years.There was significant reduction in the frequency of vasoocclusive crises per year, frequency of blood transfusion and rate of hospitalization (p{u02C2}0.05). No significant difference was detected before and after using HU as regards the frequency infections, sequestration, aplastic crises, leg ulcers and cardiac complications (p{u02C3}0.05). One patient developed leg ulcers and another one had pulmonary hypertension while on HU. None of the studied patients had evidence of avascular necrosis at starting HU, however, eight (13.3%) patients developed bone changes while on HU. Two (3.4%) patients developed stroke while on HU and they were shifted to chronic transfusion regimen. There were a significant increases in total Hb, and significant decrease in TLC and reticulocytic count (p{u02C2}0.05). A statistically significant improvement of school scores among patients was seen after HU treatment (P=0.025). A marginally significant improvement of quality of life scores was detected among patients after using HU (P=0.05)

Issued also as CD

There are no comments on this title.

to post a comment.